Patient Resources

THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).

THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.

THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

What you need to know about the THALOMID REMS® program

Your doctor will enroll you in the THALOMID REMS® program so that you can receive your medication. Use the materials below to learn more about the THALOMID REMS® program, and what you need to do.

You can take your mandatory confidential patient survey at CelgeneRiskManagement.com in English or Spanish by clicking one of the buttons below.

You can also complete your survey by using the Celgene REMS mobile app for your iPad. Please download the app to your iPad by clicking here:



Attention Females Who Can Get Pregnant

Unless you abstain from sexual intercourse with a male partner, you are required to use at the same time at least 1 highly effective birth control method and at least 1 additional effective method every time you have sex with a male. Below, you will find a printable letter that you can bring with you to your next medical appointment that discusses your reproductive health. This will help you and your healthcare provider understand what types of birth control options are best for you.

For additional information about the THALOMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: